

The Future of Haemophilia A: Discussing SubQ-8, a New Subcutaneous FVIII Development Based on Simoctocog Alfa

Chair: Andreas Tiede



ISTH 2019
Melbourne, Australia
Sunday, 7 July 2019
13:15 – 14:30
Location: Room 203 & 204



This scientific symposium is for healthcare professionals only

Organised and funded by

octapharma

The Future of Haemophilia A: Discussing SubQ-8, a New Subcutaneous FVIII Development Based on Simoctocog Alfa

13:15	Welcome and Introduction	Andreas Tiede Hannover, Germany
13:20	What Role Can Subcutaneous FVIII Play in the Future/Evolving Haemophilia A Treatment Landscape?	Robert Sidonio Atlanta, USA
13:35	Scientific Rationale and Preclinical Data Supporting Development of SubQ-8	Christoph Kannicht Berlin, Germany
13:50	Subcutaneous FVIII Therapy – Should We Be Concerned about Immunogenicity?	Andreas Tiede Hannover, Germany
14:00	Clinical Development Programme for SubQ-8	Sigurd Knaub Lachen, Switzerland
14:15	Q&A	All
14:25	Conclusions	All

FVIII replacement remains a vital part of treatment for patients with haemophilia A. From a clinical and patient perspective, the demand for a more convenient treatment is a major motivation for the development of new therapies, including novel, innovative strategies for physiological FVIII replacement. This symposium will explore the scientific and clinical rationale for the development of SubQ-8, a new subcutaneous human FVIII based on simoctocog alfa, including communication of preclinical data. We will consider the challenges and expectations surrounding SubQ-8 in the context of the current haemophilia A treatment landscape.

The information being presented represents interim data of ongoing studies of an unapproved product. The purpose of this symposium is to provide a summary of the scientific and medical progress thus far. As such, the data presented should not be interpreted as final information about the product, until such time as the product obtains regulatory approval.

